Skip to content
Research Article Open access CC BY 4.0

murA, uhpT, glpT and fosA Genes of Fosfomycin Resistance in Multi-drug Resistant E. coli Isolated from Hematological Malignancies' Patients with Blood Stream Infection

Yasmin Nabiel, Ghada Barakat

Microbiology Research Journal International · pp. 58–68 · Published 22 Mar 2021

10.9734/mrji/2021/v31i130298

Abstract

Aim: To estimate the prevalence of murA, uhpT, glpT and fosA resistance genes of fosfomycin in multidrug resistant Escherichia coli isolated from patients suffering from hematological malignancies with on top blood stream infection together with correlating this distribution to the rate of expression of AmpC, ESBLs and MBLs in such isolates. Methods: 205 blood samples collected from patients with underlying hematological malignancies were cultured to isolate E. coli strains. Multidrug resistance was detected. PCR was done to determine fosfomycin resistance genes; murA, uhpT, glpT and fosA. Results: A total of 83 (40.5%) E. coli strains were isolated from blood samples. 58 (69.9%) were found to be multidrug resistant. AmpC beta-lactamase production was deduced in 15 (25.8%) isolates. 43 (74.1%) isolates were ESBLs producers whereas 9 (15.5%) were MBL class A carbapene-mases producers. Depending on PCR results, murA gene was detected in one isolate (1.7%), uhpT gene in 3 (5.2%), glpT gene in 4 (6.9%) whereas fosA gene was found in 7 E. coli strains (12.1%). Conclusion: Fosfomycin is a promising antibiotic with limited degree of prevalence of its resistant genes; however disseminating resistance might increase in multidrug resistant E. coli

Blood stream infection fosfomycin resistance hematological malignancies multi-drug resistant E. coli.

References (28)

  1. 1 Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence [DOI]
  2. 2 Fosfomycin [DOI]
  3. 3 Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review [DOI]
  4. 4 Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance [DOI]
  5. 5 Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview [DOI]
  6. 6 Bloodstream infections in neutropenic cancer patients: A practical update [DOI]
  7. 7 Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH [DOI]
  8. 8 Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli [DOI]
  9. 9 Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies [DOI]
  10. 10 Prevalence of Fosfomycin Resistance among CTX-M-Producing Escherichia coli Clinical Isolates in Japan and Identification of Novel Plasmid-Mediated Fosfomycin-Modifying Enzymes [DOI]
  11. 11 Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance [DOI]
  12. 12 A fresh look at polymicrobial bloodstream infection in cancer patients [DOI]
  13. 13 Pediatric Carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a High-prevalence Region in the United States [DOI]
  14. 14 Detection of the plasmid-encoded fosfomycin resistance gene fosA3 in Escherichia coli of food-animal origin [DOI]
  15. 15 Glutathione-S-transferase FosA6 ofKlebsiella pneumoniaeorigin conferring fosfomycin resistance in ESBL-producingEscherichia coli [DOI]
  16. 16 Horizontal Transfer of Antimicrobial Resistance by Extended-Spectrum β Lactamase-Producing Enterobacteriaceae [DOI]
  17. 17 Antimicrobial Susceptibility and Molecular Mechanisms of Fosfomycin Resistance in Clinical Escherichia coli Isolates in Mainland China [DOI]
  18. 18 Characterization of fosA5 , a new plasmid-mediated fosfomycin resistance gene in Escherichia coli [DOI]
  19. 19 New Delhi metallo-β-lactamase: a cautionary tale [DOI]
  20. 20 New microbiological aspects of fosfomycin.
  21. 21 Prevalence of fosfomycin resistance among ESBL-producing Escherichia coli isolates in the community, Switzerland [DOI]
  22. 22 Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens.
  23. 23 Micro-organisms Associated with Febrile Neutropenia in Patients with Haematological Malignancies in a Tertiary Care Hospital in Eastern India [DOI]
  24. 24 Basic patient characteristics predict antimicrobial resistance in E. coli from urinary tract specimens: a retrospective cohort analysis of 5246 urine samples [DOI]
  25. 25 The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study [DOI]
  26. 26 Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens [DOI]
  27. 27 Antibiogram and recent incidence of multi-drug resistant carbapenemase producing Escherichia coli isolated from paediatric patients [DOI]
  28. 28 Fosfomycin: Mechanism and Resistance [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

30

Page views

0

PDF downloads

4

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.